ライフサイエンスコーパス: breast-conserving surgery

1 bserved in stage II BC patients treated with breast conserving surgery.

2 lymph nodes and had completed mastectomy or breast-conserving surgery.

3 with standard whole-breast irradiation after breast-conserving surgery.

4 equencing of TAM and radiotherapy (RT) after breast-conserving surgery.

5 81 to 2.37) were the strongest predictors of breast-conserving surgery.

6 racteristics were associated with the use of breast-conserving surgery.

7 , 60% responded and 48% underwent successful breast-conserving surgery.

8 therapy was given to 86% of patients who had breast-conserving surgery.

9 re twice as likely as other women to undergo breast-conserving surgery.

10 with BC treated with radiotherapy (RT) after breast-conserving surgery.

11 were less likely than other women to undergo breast-conserving surgery.

12 t and transient effect on the rate of use of breast-conserving surgery.

13 All had had breast-conserving surgery.

14 t also influences local recurrence following breast-conserving surgery.

15 ly-stage invasive breast cancer treated with breast-conserving surgery.

16 lity able to downstage tumors and facilitate breast-conserving surgery.

17 size, <=5 cm) who were scheduled to undergo breast-conserving surgery.

18 ical tumor characteristics; and frequency of breast-conserving surgery.

19 y, and cost of mandatory radiation following breast-conserving surgery.

20 ll benefit from neoadjuvant therapy enabling breast-conserving surgery.

21 te assessment of tumor margin involvement in breast-conserving surgery.

22 tions with a tumor bed boost (WBI arm) after breast-conserving surgery.

23 h in intraoperative margin assessment during breast-conserving surgery.

24 of clinical application of gGlu-HMRG during breast-conserving surgery.

25 The majority of patients (76.1%) underwent breast-conserving surgery.

26 ndular breast tissue is an important step in breast-conserving surgery.

27 e detection of residual cancer tissue during breast-conserving surgery.

28 h ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery.

29 were submitted for surgery, and 10 underwent breast-conserving surgery.

30 thod for intraoperative margin assessment in breast-conserving surgeries.

31 for potential intraoperative use in guiding breast-conserving surgeries.

32 igher morbidity for mastectomies (4.0%) than breast conserving surgery (1.6%, P < 0.001).

33 They underwent breast-conserving surgery (1 cm margin) with axillary no

34 and experienced no recurrence, 963 underwent breast-conserving surgery, 263 mastectomy without recons

35 eral invasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral ma

36 After breast-conserving surgery, 90% of local recurrences occu

37 For those who have undergone breast-conserving surgery, a post-treatment mammogram sh

38 For women who have undergone breast-conserving surgery, a post-treatment mammogram sh

39 After breast-conserving surgery, a total dose of 50.4 Gy was d

40 ined as omissions of radiation therapy after breast-conserving surgery, adjuvant chemotherapy after r

41 Breast-conserving surgery, adjuvant systemic therapy, an

42 st [10.00-12.50 Gy/4-5 fractions]) following breast-conserving surgery administered in community-base

43 ults support the treatment of MO tumors with breast conserving surgery after a detailed clinical eval

44 The impact of tumor biology on the rate of breast-conserving surgery after neoadjuvant chemotherapy

45 gislation, we determined whether the rate of breast-conserving surgery after the legislation was diff

46 with stage I-IIA breast cancer treated with breast-conserving surgery, age >= 49 years, were randoml

47 ries <10% risk of any local recurrence after breast-conserving surgery alone.

48 an overall survival advantage compared with breast-conserving surgery alone.

49 We examined the trend over time in use of breast-conserving surgery among patients in four sites (

50 surgery in both states and the correlates of breast-conserving surgery among women eligible for the p

51 I, 1.19 to 1.73), but less likely to undergo breast-conserving surgery among women undergoing definit

52 2.6%) received radiation (6474 [96.1%] after breast-conserving surgery and 344 [13.0%] after mastecto

53 ostoperative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatme

54 negative breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy

55 the results of studies of radiotherapy after breast-conserving surgery and after mastectomy, and an i

56 de, and paclitaxel chemotherapy, followed by breast-conserving surgery and axillary lymph node dissec

57 These results support the use of breast-conserving surgery and definitive breast irradiat

58 ng the treatment of DCIS of the breast using breast-conserving surgery and definitive breast irradiat

59 minal A breast cancer that were treated with breast-conserving surgery and endocrine therapy alone, t

60 inal A-like breast cancer, who had undergone breast-conserving surgery and had an Eastern Cooperative

61 29-83 years (mean, 55.9 years) treated with breast-conserving surgery and irradiation (n = 183) unde

62 erly women have with various providers about breast-conserving surgery and mastectomy.

63 t knowledge gaps in the field of oncoplastic breast-conserving surgery and nipple-sparing or skin-spa

64 rom 2009 through 2011, to determine rates of breast-conserving surgery and pCR after chemotherapy by

65 ive breast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chem

66 aged 36 or younger at diagnosis treated with breast-conserving surgery and radiation therapy (> or =

67 sociated with LR among patients treated with breast-conserving surgery and radiation therapy.

68 breast cancer patients who were treated with breast-conserving surgery and radiation were analyzed.

69 We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mu

70 ease in the proportion of patients receiving breast-conserving surgery and radiotherapy with a simult

71 years was 0.85% among patients who received breast-conserving surgery and radiotherapy with RNI; 0.5

72 For patients treated with breast-conserving surgery and RT, the 5-year cumulative

73 All 5210 patients underwent breast-conserving surgery and SLN dissection.

74 S treated with vs without the RT boost after breast-conserving surgery and WBRT.

75 , but not both, were permitted), who had had breast-conserving surgery and were receiving adjuvant en

76 658 women who had undergone breast-conserving surgery and who were receiving adjuvan

77 -low-risk ductal carcinoma in situ following breast-conserving surgery and whole breast radiotherapy.

78 ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (

79 tinel lymph node metastases and will receive breast-conserving surgery and whole-breast RT with or wi

80 able analyses, mastectomy with radiation (vs breast conserving surgery) and Asian, Black, or American

81 nded to the survey (40.0%; 356 had undergone breast-conserving surgery, and 291 had undergone mastect

82 reported, 20% do not receive radiation after breast-conserving surgery, and 30% to 70% of women with

83 reases the likelihood that women will choose breast-conserving surgery, and enhances patient knowledg

84 osed pure DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or wit

85 ated with older age, total mastectomy versus breast-conserving surgery, and reconstructive surgery.

86 study of persons undergoing cholecystectomy, breast-conserving surgery, anterior cruciate ligament re

87 Margins of wide local excisions in breast conserving surgery are tested through histology,

88 High positive margin rates in oncologic breast-conserving surgery are a pressing clinical proble

89 as minimal mortality, recurrence rates after breast-conserving surgery are significant, and half are

90 t cancer (cT1-2, N0-1) who were eligible for breast-conserving surgery as per clinicoradiological ass

91 Breast-conserving surgery at primary diagnosis, locoregi

92 and institutions on the use of mastectomy or breast conserving surgery (BCS) among elderly women with

93 Breast conserving surgery (BCS) is a recommended treatme

94 reservation of breast cosmesis with a single breast conserving surgery (BCS) is essential for surgeon

95 ons exist for early stage breast cancer: (1) breast conserving surgery (BCS), (2) mastectomy with rec

96 regarding NAC, adjuvant chemotherapy (aCT), breast conserving surgery (BCS), bilateral mastectomy (B

97 cancer have a choice between mastectomy and breast conserving surgery (BCS).

98 the resection margin is a major challenge in breast conserving surgery (BCS).

99 SL) and wire-guided localization (WGL) after breast conserving surgery (BCS).

100 baseline (n = 124), 44% of patients received breast-conserving surgery (BCS) after anastrozole compar

101 Compared with breast-conserving surgery (BCS) alone, there was a decre

102 all patients with invasive cancer receiving breast-conserving surgery (BCS) and among patients under

103 der with stage I breast cancers treated with breast-conserving surgery (BCS) and endocrine therapy (E

104 ified radical mastectomy (MRM) compared with breast-conserving surgery (BCS) and radiation therapy (R

105 June 1999, demonstrated that tamoxifen after breast-conserving surgery (BCS) and radiotherapy for duc

106 Breast-conserving surgery (BCS) and radiotherapy reduce

107 y-stage breast cancer patients, treated with breast-conserving surgery (BCS) and whole-breast irradia

108 Inadequate margins in breast-conserving surgery (BCS) are associated with an i

109 Positive margins following breast-conserving surgery (BCS) are often identified on

110 tutes of Health Consensus Statement in 1990, breast-conserving surgery (BCS) became more common while

111 lesions may decrease the reoperation rate in breast-conserving surgery (BCS) compared with rates afte

112 tion exists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in

113 quent ipsilateral breast events (IBEs) after breast-conserving surgery (BCS) for ductal carcinoma in

114 aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (E

115 standard for the treatment of DCIS; however, breast-conserving surgery (BCS) has been adopted as the

116 astectomy was performed in 1464 patients and breast-conserving surgery (BCS) in 1395.

117 These 25,000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherap

118 Breast-conserving surgery (BCS) is a commonly utilized t

119 Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment

120 PURPOSE Breast-conserving surgery (BCS) is an effective treatmen

121 Breast-conserving surgery (BCS) is commonly used for the

122 Although breast-conserving surgery (BCS) is often assumed to resu

123 lateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) is relatively high.

124 e database for women with DCIS who underwent breast-conserving surgery (BCS) or mastectomy.

125 e identification of the tumor margins during breast-conserving surgery (BCS) remains a challenge give

126 an expected rates of radiation therapy after breast-conserving surgery (BCS) suggest undertreatment.

127 igh-volume surgeons were more likely to have breast-conserving surgery (BCS) than those managed by lo

128 reated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) to prevent locoregional

129 iest form of breast cancer, are treated with breast-conserving surgery (BCS) when feasible.

130 Cohort studies show better survival after breast-conserving surgery (BCS) with postoperative radio

131 Guidelines recommend breast-conserving surgery (BCS) with radiation or mastec

132 36; 95% CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v

133 Strategies were breast-conserving surgery (BCS), BCS with 50-Gy radiatio

134 on in the risk of local recurrence following breast-conserving surgery (BCS), even in "low-risk" popu

135 delivering partial-breast irradiation after breast-conserving surgery (BCS).

136 , and to not receive radiation therapy after breast-conserving surgery (BCS).

137 reated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS).

138 c 70-gene risk score test result and who had breast-conserving surgery (BCS).

139 s unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS).

140 e primary treatment option for most women is breast-conserving surgery (BCS).

141 to evaluate residual tumor immediately after breast-conserving surgery (BCS).

142 ologically eligible for either mastectomy or breast-conserving surgery (BCS; n = 125).

143 mor characteristics, treatments (mastectomy, breast-conserving surgery [BCS] with radiation therapy o

144 Breast-conserving surgery combined with axillary lymph n

145 Breast-conserving surgery combined with radiation therap

146 test the benefit of radiotherapy (RT) after breast-conserving surgery compared with observation.

147 for patients with early breast cancer after breast-conserving surgery compared with whole-breast irr

148 wly diagnosed breast cancer who were offered breast-conserving surgery consented from September 2006

149 To ensure successful breast conserving surgeries, efficient tumour margin res

150 h lower risks of invasive breast cancer than breast conserving surgery, even when accompanied by radi

151 Although breast-conserving therapy (breast-conserving surgery followed by radiotherapy) has

152 cer in a cohort of young women who underwent breast-conserving surgery followed by radiotherapy.

153 ontrol are comparable to outcomes seen after breast-conserving surgery followed by standard whole-bre

154 Involved or close pathological margins after breast conserving surgery for early stage, invasive brea

155 edicts a late relapse a decade or more after breast-conserving surgery for early breast cancer might

156 Radiotherapy (RT) after breast-conserving surgery for early-stage disease has be

157 exists regarding the optimal margin width in breast-conserving surgery for invasive breast cancer.

158 two patients > 40 years of age who underwent breast-conserving surgery for node-negative breast cance

159 Whole-breast irradiation after breast-conserving surgery for patients with early-stage

160 atified random sample of women who underwent breast-conserving surgery for primary DCIS between 2008

161 controlled trial that recruited women after breast-conserving surgery for pT1-3pN0-3aM0 invasive car

162 were at least 55 years of age, had undergone breast-conserving surgery for T1N0 (tumor size <2 cm and

163 men aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal a

164 ible studies reported on patients undergoing breast conserving surgery (for stages I-III breast cance

165 rs many women from receiving the benefits of breast-conserving surgery, forcing them to choose a mast

166 ns that were grossly examined at the time of breast conserving surgery from January 2014 to July 2020

167 pective database of DCIS patients undergoing breast-conserving surgery from 1978 to 2010.

168 ninety-one patients with DCIS who underwent breast-conserving surgery from 1996 to 2010 were identif

169 urgery, those who had mastectomy rather than breast conserving surgery had a lower 25 year cumulative

170 At a time when breast-conserving surgery has become more widely used, t

171 Although mastectomy and breast conserving surgery have low risk for complication

172 imately 500 patients treated with APBI after breast-conserving surgery have been published.

173 The rate of breast-conserving surgery in both states and the correla

174 The rate of breast-conserving surgery in both states was much higher

175 the treatment of breast cancer on the use of breast-conserving surgery in clinical practice.

176 Although the rate of breast-conserving surgery in each state was higher than

177 ible for the procedure, nearly 75% underwent breast-conserving surgery in Massachusetts and nearly ha

178 Optimal therapy following breast-conserving surgery in older adults with low-risk,

179 ilable on the omission of radiotherapy after breast-conserving surgery in older women with hormone re

180 APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast

181 APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast

182 In all patients, breast-conserving surgery included complete gross excisi

183 Hypofractionated WBI after breast conserving surgery increased among women with ear

184 proportion of all women who were treated by breast-conserving surgery increased, and because this ap

185 Breast conserving surgery is the preferred treatment for

186 Identifying tumour margins during breast-conserving surgeries is a persistent challenge.

187 Breast-conserving surgery is a more complex treatment th

188 Although breast-conserving surgery is a standard approach for pat

189 arly breast cancer, standard treatment after breast-conserving surgery is adjuvant whole-breast radio

190 Locoregional failure after breast-conserving surgery is associated with increased r

191 The surgical margin status after breast-conserving surgery is considered the strongest pr

192 vention when invasive local recurrence after breast-conserving surgery is detected.

193 st cancer, or ductal carcinoma in situ (when breast-conserving surgery is planned) or are pregnant sh

194 ), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant sh

195 e striking fact about local recurrence after breast-conserving surgery is that most occurs in the are

196 ancer after 10 years, but the risk following breast-conserving surgery (lumpectomy) has yet to be det

197 ed who underwent mastectomy (N = 10,471) and breast conserving surgery (N = 16,517).

198 For women who had breast-conserving surgery (n = 49 166), the authors exam

199 Fifty-nine percent of women underwent breast-conserving surgery, of whom 81% received radiatio

200 oportion undergoing an inappropriate form of breast-conserving surgery (omission of radiotherapy, axi

201 First, the effect of oncoplastic breast-conserving surgery on quality of life and the opt

202 ive breast cancer compared to treatment with breast conserving surgery only (0.86, 0.62 to 1.21).

203 -conserving surgery plus postoperative RT or breast-conserving surgery only and followed for a median

204 th stage 0-II breast cancer and treated with breast-conserving surgery or mastectomy and reconstructi

205 rom 30 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or reg

206 decision aid were 25% more likely to choose breast-conserving surgery over mastectomy (risk ratio, 1

207 e were no more likely than others to undergo breast-conserving surgery (P >.2), but these women were

208 m PET (DeltaBF cutoff = -30%; P = 0.03), non-breast-conserving surgery (P = 0.04), and the absence of

209 cer stage I and II were randomly assigned to breast-conserving surgery plus postoperative RT or breas

210 with lower mortality than that achieved with breast-conserving surgery plus radiation.

211 t;0.0001) and, for angiosarcomas, the RR for breast-conserving surgery plus radiotherapy versus maste

212 0,681 hernia, and 0.8% and 0.8% after 42,489 breast-conserving surgery procedures.

213 initive surgical therapy, radiotherapy after breast-conserving surgery, radiation therapy after maste

214 Most women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiati

215 In the randomized trials, radiotherapy after breast-conserving surgery reduced mortality from both br

216 ould foster intraoperative histopathology in breast-conserving surgery, reducing the need for a secon

217 e invasive breast cancer to +/- RT following breast-conserving surgery: SweBCG91-RT (stage I-II, no a

218 he coming years due to the increasing use of breast-conserving surgery techniques.

219 SDI and Medicare coverage had lower rates of breast-conserving surgery than other women (43.2% vs. 49

220 ess likely to undergo standard therapy after breast-conserving surgery than other women.

221 g all surgically treated patients (including breast-conserving surgery), the CPM rate increased by 14

222 to treat DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 18

223 cancer </= 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10

224 ary tumour to avoid mastectomy, and to allow breast-conserving surgery to be done.

225 Adjuvant radiotherapy is prescribed after breast-conserving surgery to reduce the risk of local re

226 temporal trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CP

227 without radiation); axillary dissection; and breast-conserving surgery versus mastectomy among women

228 Receipt of breast-conserving surgery versus mastectomy.

229 ts with early breast cancer choosing between breast-conserving surgery vs mastectomy.

230 study of patients undergoing mastectomy and breast conserving surgery was performed from the Nationa

231 the overall rate of radiation therapy after breast-conserving surgery was 80% in the quality improve

232 n the observational data, radiotherapy after breast-conserving surgery was associated with much large

233 Breast-conserving surgery was more frequently performed

234 RT was required if breast-conserving surgery was performed but was elective

235 Breast-conserving surgery was possible in 66.6% of the p

236 Breast-conserving surgery was recommended by surgeons an

237 The rate of breast-conserving surgery was up to 8.7 percent higher t

238 The rates of breast-conserving surgery were 66.7%, 57.9%, and 68.9% i

239 ve and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to e

240 cer or ductal carcinoma in situ treated with breast-conserving surgery were centrally randomly assign

241 invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled from 28 centres

242 r PgR+) primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 mo

243 Rates of breast-conserving surgery were significantly higher in p

244 Rates of breast-conserving surgery were similar between the two g

245 ancer directly in the surgical cavity during breast-conserving surgery, which could potentially contr

246 e tumors operable and increases the rates of breast-conserving surgery, while achieving similar long-

247 e, approximately 3% of patients treated with breast-conserving surgery will have an in-breast local r

248 In breast-conserving surgery, wire or seed localization and

249 ith stages I or II breast cancer, excised by breast conserving surgery with negative margins, were el

250 ith radiotherapy 19.8% (16.2% to 23.4%), and breast conserving surgery with no radiotherapy recorded

251 gery with radiotherapy 8.6% (5.9% to 15.5%), breast conserving surgery with no radiotherapy recorded

252 st conserving surgery with radiotherapy, and breast conserving surgery with no radiotherapy recorded.

253 In women who underwent breast conserving surgery with or without radiotherapy,

254 8.2% (95% conference interval 7.0% to 9.4%), breast conserving surgery with radiotherapy 19.8% (16.2%

255 ast cancer (mastectomy 6.5% (4.9% to 10.9%), breast conserving surgery with radiotherapy 8.6% (5.9% t

256 ancer death appeared similar for mastectomy, breast conserving surgery with radiotherapy, and breast

257 The Z11102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that i

258 ilable published world medical literature on breast-conserving surgery with and without postoperative

259 gically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear ra

260 mastectomy with axillary node dissection or breast-conserving surgery with axillary node dissection

261 =3 cm in the largest dimension) treated with breast-conserving surgery with clear excision margins an

262 like HER2 negative carcinoma <= 20 mm) after breast-conserving surgery with negative margins.

263 lop ipsilateral invasive breast cancer after breast-conserving surgery with or without adjuvant radio

264 situ from patients who had been treated with breast-conserving surgery with or without postoperative

265 of follow-up of randomised trials comparing breast-conserving surgery with or without radiotherapy.

266 Compared with breast-conserving surgery with radiation (10-year mortal

267 agnosed between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserv

268 es (95% CI, 1.02 to 1.73) more likely to get breast-conserving surgery with radiation than other type

269 ment options for early breast cancer include breast-conserving surgery with radiation therapy (RT) or

270 py based on National Guidelines as receiving breast-conserving surgery with radiation therapy and axi

271 and use of definitive surgery (mastectomy or breast-conserving surgery with radiation v breast-conser

272 Locoregional treatment comparing 3 groups: breast-conserving surgery with radiotherapy (BCS+RT), ma

273 rgery and radiotherapy with RNI; 0.55% after breast-conserving surgery with radiotherapy without RNI;

274 ction), 551 (85.2%) confirmed treatment with breast-conserving surgery with RT (n = 315) or mastectom

275 sis showed no significant difference between breast-conserving surgery with RT (referent) and mastect

276 The findings support equivalence of breast-conserving surgery with RT and mastectomy and rec

277 Breast-conserving surgery with RT or mastectomy and reco

278 However, breast-conserving surgery with RT was associated with cl

279 reported that their surgeon did not discuss breast-conserving surgery with them.

280 gy (ASTRO) guideline on surgical margins for breast-conserving surgery with whole-breast irradiation

281 metastatic SLNs who are planning to undergo breast-conserving surgery with whole-breast radiotherapy

282 e to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy

283 ductal carcinoma in situ (DCIS) treated with breast-conserving surgery without adjuvant radiation the

284 xols was lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was mo

285 r breast-conserving surgery with radiation v breast-conserving surgery without radiation); axillary d

286 Among women who had breast-conserving surgery, women with SSDI and Medicare